The EU regulatory data protection regime is facing one of the biggest shake-ups in 20 years, with proposals by the European Commission to reduce the baseline period of RDP and introduce a system under which a set of top-up protection periods could be granted under certain conditions.
While the move to cut RDP is controversial in itself, companies that will be affected by this change – R&D-based and generic/biosimilar firms alike – are still pretty much in the dark as to exactly